BACKGROUND: The purpose of this study was to evaluate the effect of an aprepitant, neurokinin-1(NK1) receptor antagonist, for reducing postoperative nausea and vomiting (PONV) for up to 24 hours in patients regarded as high risk undergoing gynecological surgery with intravenous patient-controlled analgesia (IV PCA) using fentanyl. METHODS: In this randomized, open label, case-control study 84 gynecological surgical patients receiving a standardized general anesthesia were investigated. Patients were randomly allocated to receive aprepitant 80 mg P.O. approximately 2-3 hours before operation (aprepitant group) or none (control group). All patients received ramosetron 0.3 mg IV after induction of anesthesia. The incidence of PONV, severity of nausea, and use of rescue antiemetics were evaluated for up to 24 hours postoperatively. RESULTS: The incidence of nausea was significantly lower in the aprepitant group (50.0%) compared to the control group (80.9%) during the first 24 hours following surgery. The incidence of vomiting was significantly lower in the aprepitant group (4.7%) compared to the control group (42.8%) during the first 24 hours following surgery. In addition, the severity of nausea was less among those in the aprepitant group compared with the control group over a period of 24 hours post-surgery (P < 0.05). Use of rescue antiemetics was lower in the aprepitant group than in the control group during 24 hours postoperatively (P < 0.05). CONCLUSIONS: In patients regarded as high risk undergoing gynecological surgery with IV PCA usingfentanyl, the aprepitant plus ramosetron ware more effective than ramosetron alone to decrease the incidence of PONV, use of rescue antiemetics and nausea severity for up to 24 hours postoperatively.
RCT Entities:
BACKGROUND: The purpose of this study was to evaluate the effect of an aprepitant, neurokinin-1(NK1) receptor antagonist, for reducing postoperative nausea and vomiting (PONV) for up to 24 hours in patients regarded as high risk undergoing gynecological surgery with intravenous patient-controlled analgesia (IV PCA) using fentanyl. METHODS: In this randomized, open label, case-control study 84 gynecological surgical patients receiving a standardized general anesthesia were investigated. Patients were randomly allocated to receive aprepitant 80 mg P.O. approximately 2-3 hours before operation (aprepitant group) or none (control group). Allpatients received ramosetron 0.3 mg IV after induction of anesthesia. The incidence of PONV, severity of nausea, and use of rescue antiemetics were evaluated for up to 24 hours postoperatively. RESULTS: The incidence of nausea was significantly lower in the aprepitant group (50.0%) compared to the control group (80.9%) during the first 24 hours following surgery. The incidence of vomiting was significantly lower in the aprepitant group (4.7%) compared to the control group (42.8%) during the first 24 hours following surgery. In addition, the severity of nausea was less among those in the aprepitant group compared with the control group over a period of 24 hours post-surgery (P < 0.05). Use of rescue antiemetics was lower in the aprepitant group than in the control group during 24 hours postoperatively (P < 0.05). CONCLUSIONS: In patients regarded as high risk undergoing gynecological surgery with IV PCA using fentanyl, the aprepitant plus ramosetron ware more effective than ramosetron alone to decrease the incidence of PONV, use of rescue antiemetics and nausea severity for up to 24 hours postoperatively.
Authors: Z Gesztesi; P E Scuderi; P F White; W Wright; R H Wender; R D'Angelo; L S Black; P L Dalby; D MacLean Journal: Anesthesiology Date: 2000-10 Impact factor: 7.892
Authors: S Khalil; L Philbrook; M Rabb; L Wells; T Aves; G Villanueva; M Amhan; A Z Chuang; N A Lemak Journal: J Clin Anesth Date: 1999-11 Impact factor: 9.452
Authors: F D Tattersall; W Rycroft; M Cumberbatch; G Mason; S Tye; D J Williamson; J J Hale; S G Mills; P E Finke; M MacCoss; S Sadowski; E Ber; M Cascieri; R G Hill; D E MacIntyre; R J Hargreaves Journal: Neuropharmacology Date: 2000-02-14 Impact factor: 5.250
Authors: Flavia Longo; Giovanni Mansueto; Vittoria Lapadula; Rita De Sanctis; Silvia Quadrini; Roberta Grande; Bruno Gori; Amelia Altavilla; I D'Antoni; Ester Del Signore; Luciano Stumbo; Cristina De Luca; Barbara Cimadon; Enrico Cortesi; Teresa Gamucci; Marisa Di Seri Journal: Support Care Cancer Date: 2010-06-16 Impact factor: 3.603
Authors: F D Tattersall; W Rycroft; B Francis; D Pearce; K Merchant; A M MacLeod; T Ladduwahetty; L Keown; C Swain; R Baker; M Cascieri; E Ber; J Metzger; D E MacIntyre; R G Hill; R J Hargreaves Journal: Neuropharmacology Date: 1996 Impact factor: 5.250
Authors: Christian C Apfel; Kari Korttila; Mona Abdalla; Heinz Kerger; Alparslan Turan; Ina Vedder; Carmen Zernak; Klaus Danner; Ritva Jokela; Stuart J Pocock; Stefan Trenkler; Markus Kredel; Andreas Biedler; Daniel I Sessler; Norbert Roewer Journal: N Engl J Med Date: 2004-06-10 Impact factor: 91.245
Authors: Isaac W Therneau; Erin E Martin; Juraj Sprung; Todd A Kellogg; Darrell R Schroeder; Toby N Weingarten Journal: Obes Surg Date: 2018-01 Impact factor: 4.129
Authors: Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke Journal: Cochrane Database Syst Rev Date: 2020-10-19